Banque Cantonale Vaudoise Raises Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Banque Cantonale Vaudoise lifted its holdings in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 108.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,823 shares of the medical equipment provider's stock after acquiring an additional 15,535 shares during the quarter. Banque Cantonale Vaudoise's holdings in Zimmer Biomet were worth $3,219,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors also recently modified their holdings of the company. Price T Rowe Associates Inc. MD boosted its stake in shares of Zimmer Biomet by 12.9% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,642,801 shares of the medical equipment provider's stock valued at $1,404,638,000 after purchasing an additional 1,215,935 shares in the last quarter. American Century Companies Inc. increased its holdings in Zimmer Biomet by 12.6% in the second quarter. American Century Companies Inc. now owns 6,463,845 shares of the medical equipment provider's stock worth $701,521,000 after purchasing an additional 722,041 shares in the last quarter. Van ECK Associates Corp increased its holdings in shares of Zimmer Biomet by 12.4% during the third quarter. Van ECK Associates Corp now owns 3,736,761 shares of the medical equipment provider's stock valued at $391,239,000 after acquiring an additional 411,163 shares in the last quarter. Victory Capital Management Inc. boosted its position in Zimmer Biomet by 6.7% in the second quarter. Victory Capital Management Inc. now owns 3,364,624 shares of the medical equipment provider's stock worth $365,163,000 after purchasing an additional 211,637 shares during the last quarter. Finally, Boston Partners lifted its position in shares of Zimmer Biomet by 26.3% during the 1st quarter. Boston Partners now owns 3,314,939 shares of the medical equipment provider's stock valued at $437,413,000 after buying an additional 691,191 shares during the last quarter. 88.89% of the stock is currently owned by institutional investors.

Zimmer Biomet Trading Down 1.5 %

ZBH stock traded down $1.64 during midday trading on Wednesday, hitting $109.31. 1,476,375 shares of the company's stock were exchanged, compared to its average volume of 1,497,754. The company has a market cap of $21.76 billion, a PE ratio of 20.78, a price-to-earnings-growth ratio of 2.08 and a beta of 1.02. The stock's fifty day moving average price is $106.65 and its 200-day moving average price is $109.86. Zimmer Biomet Holdings, Inc. has a one year low of $101.47 and a one year high of $133.90. The company has a debt-to-equity ratio of 0.38, a quick ratio of 0.70 and a current ratio of 1.36.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 EPS for the quarter, meeting the consensus estimate of $1.74. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The firm's revenue for the quarter was up 4.1% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.65 earnings per share. Research analysts predict that Zimmer Biomet Holdings, Inc. will post 7.99 earnings per share for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Shareholders of record on Monday, September 30th were given a dividend of $0.24 per share. The ex-dividend date of this dividend was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.88%. Zimmer Biomet's dividend payout ratio is currently 18.25%.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ZBH shares. Robert W. Baird dropped their target price on shares of Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating for the company in a report on Thursday, August 8th. Raymond James decreased their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an "outperform" rating on the stock in a research note on Monday, October 14th. JPMorgan Chase & Co. cut their price target on shares of Zimmer Biomet from $125.00 to $120.00 and set a "neutral" rating on the stock in a report on Monday, September 16th. Truist Financial raised their price target on shares of Zimmer Biomet from $112.00 to $117.00 and gave the company a "hold" rating in a report on Friday, November 1st. Finally, Evercore ISI cut their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, Zimmer Biomet currently has a consensus rating of "Hold" and an average target price of $123.22.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.